Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Cash from Operations (2024 - 2025)

Prelude Therapeutics' Cash from Operations history spans 2 years, with the latest figure at 23119000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 211.45% year-over-year to 23119000.0; the TTM value through Dec 2025 reached 56302000.0, up 45.28%, while the annual FY2025 figure was 56302000.0, 45.28% up from the prior year.
  • Cash from Operations for Q4 2025 was 23119000.0 at Prelude Therapeutics, up from 19115000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 23119000.0 in Q4 2025 and bottomed at 34231000.0 in Q1 2025.